NCT02132468 - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions

Neuroendocrine Tumors

Interventions

DRUG

fosbretabulin tromethamine

60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity

Trial Locations (5)

Montefiore, The Bronx

Duke University Medical Center, Durham

Markey Cancer Center, Clinical Research Office, Lexington

Froedtert Hospital, Medicial College of Wisconsin, Milwaukee

Stanford University School of Medicine, Stanford